Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) has earned an average rating of "Moderate Buy" from the twenty-three analysts that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, six have assigned a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $1,052.90.

A number of analysts have recently issued reports on REGN shares. Canaccord Genuity Group began coverage on Regeneron Pharmaceuticals in a research report on Tuesday. They set a "hold" rating and a $165.00 target price on the stock. Leerink Partners reiterated a "market perform" rating and set a $1,077.00 target price (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. Truist Financial reduced their price objective on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a "buy" rating on the stock in a research note on Friday, November 1st. Oppenheimer lowered their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an "outperform" rating for the company in a report on Wednesday, November 6th. Finally, Citigroup assumed coverage on Regeneron Pharmaceuticals in a research note on Thursday, November 14th. They set a "neutral" rating and a $895.00 price objective on the stock.

Institutional Trading of Regeneron Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in REGN. Mizuho Securities USA LLC lifted its stake in shares of Regeneron Pharmaceuticals by 625.5% in the 3rd quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company's stock valued at $62,382,000 after acquiring an additional 51,162 shares during the last quarter. Tri Locum Partners LP grew its holdings in shares of Regeneron Pharmaceuticals by 104.5% during the second quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company's stock worth $18,410,000 after purchasing an additional 8,949 shares during the last quarter. Simplify Asset Management Inc. increased its stake in shares of Regeneron Pharmaceuticals by 50.8% in the third quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company's stock valued at $10,082,000 after buying an additional 3,231 shares during the period. Catalytic Wealth RIA LLC bought a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $1,334,000. Finally, Daiwa Securities Group Inc. boosted its position in Regeneron Pharmaceuticals by 12.3% during the 3rd quarter. Daiwa Securities Group Inc. now owns 20,384 shares of the biopharmaceutical company's stock worth $21,428,000 after buying an additional 2,234 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Down 0.9 %

Shares of REGN traded down $6.37 during midday trading on Thursday, reaching $708.25. 990,833 shares of the company were exchanged, compared to its average volume of 562,569. Regeneron Pharmaceuticals has a 1-year low of $693.00 and a 1-year high of $1,211.20. The stock has a 50-day moving average price of $833.09 and a 200-day moving average price of $998.86. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The company has a market cap of $77.83 billion, a price-to-earnings ratio of 17.53, a P/E/G ratio of 2.19 and a beta of 0.08.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.